Eric Lindley, MD
Interventional Cardiology · Salt Lake City, UTNPI 1629221841
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $12,200 of the $18,357 with a category attached, or 66.5%. Abbott accounts for 92.5% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2019 at $11,442 and has fallen 84.5% since, to $1,778 in 2025.
Across 82 payments — averaging $223.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$17K
- Edwards Lifesciences$750
- Boston Scientific$548
- Medtronic$62
- Abiomed$15
Across 13 payments — averaging $1044.92 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abbott$14K
What the payments were for
- Speaking & faculty fees$12,20066%
- Travel & lodging$3,84821%
- Food & beverage$2,30913%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 47 | $16,982 |
| Edwards Lifesciences | 11 | $750 |
| Boston Scientific | 22 | $548 |
| Medtronic | 1 | $62 |
| Abiomed | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$18,357 in reported general payments places this provider in the 75th percentile of 45 interventional cardiology providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ClopidogrelClopidogrel Bisulfate | 37 | $498 |
| Metoprolol Succinate | 32 | $344 |
| Rosuvastatin Calcium | 24 | $275 |
| Atorvastatin Calcium | 25 | $242 |
| Carvedilol | 13 | $138 |
| Losartan Potassium | 15 | $127 |
Paid to pharmacies, not to this prescriber.
Other interventional cardiology in Salt Lake City
- Vamsee YagantiSalt Lake City$390K
- Anwar TandarSalt Lake City$131K
- Stavros DrakosSalt Lake City$79K
- Frederick WeltSalt Lake City$26K
- Scott HackingSalt Lake City$22K
- Lee LinstrothSalt Lake City$14K
- Theophilus OwanSalt Lake City$9K
- Diana MeloSalt Lake City$4K
- Tara JonesSalt Lake City$4K
- Scott BrewsterSalt Lake City$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.